Compare EVLV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | PHAT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 988.3M | 942.6M |
| IPO Year | N/A | 2019 |
| Metric | EVLV | PHAT |
|---|---|---|
| Price | $6.74 | $14.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.13 | ★ $17.60 |
| AVG Volume (30 Days) | ★ 3.2M | 838.1K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $136,501,000.00 | ★ $147,190,000.00 |
| Revenue This Year | $41.14 | $218.59 |
| Revenue Next Year | $14.60 | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 43.16 | ★ 460.30 |
| 52 Week Low | $2.64 | $2.21 |
| 52 Week High | $8.91 | $16.27 |
| Indicator | EVLV | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 55.49 |
| Support Level | $6.10 | $14.12 |
| Resistance Level | $6.85 | $16.27 |
| Average True Range (ATR) | 0.27 | 0.72 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 88.97 | 29.84 |
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.